Positron emission tomography findings in heavy users of MDMA (multiple letter) [5]

Lancet

Volumn 353, Issue 9152, 1999, Pages 592-593

  Holland, J ^a   McCann, U D ^a   Szabo, Z ^a   Scheffel, U ^a   Dannals, R F ^a   Ricaurte, G A ^a  

^a BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT;

HUMAN; LETTER; NEUROTOXICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; NOTE; SCINTISCANNING;

BRAIN; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033550642     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)75651-8     Document Type: Letter

References (3)

1. UD McCann J Tuan G Hatzidimitriou GA Ricaurte Selective serotonin reuptake inhibitors dissociate fenfluramine's anorectic and neurotoxic effects: Importance of dose, species and drug J Pharmacol Exp Ther 281 1997 1487 1498
2. GA Ricaurte LE DeLanney I Irwin Toxic effects of 3,4-mathylenedioxy-methamphetamine on central serotonergic neurons in the primate: Importance of route and frequency of drug administration Brain Res 446 1988 165 168
3. U McCann M Mertl G Ricaurte Methylenemethamphetamine (MDMA, “Ecstasy”) Tarter R Ammerman R Ott P In: Handbook of substance abuse: neurobehavioural pharmacology 1998 Plenum Press New York 567 578